Overview

A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2026-09-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.

Phase:

PHASE1

Details

Lead Sponsor:

NSC-Therapeutics

Collaborator:

NeuroScios GmbH